drugset
drugset / Trial / NCT02873208

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCT02873208 ↗

Phase 3 Completed 266 enrolled Alkermes, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

Timeline

Start
2016-08-07
Primary completion
2019-10-17
Completion
2019-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 10 mg Oral
Subject Olanzapine Small molecule 15 mg Oral
Subject Olanzapine Small molecule 20 mg Oral
Subject Samidorphan Small molecule 10 mg Oral

Indications

schizophrenia